METTL3 is a Significant Focus in Cancer Research
Monday, 02 October 2023
Methyltransferase-like 3 (METTL3) is a 70 kDa protein, 580 amino acids in length. It is the principal catalytic agent for most of the N6– methyladenosine (m6A) modifications that occur in eukaryotic cell mRNA. METTL3 typically places methyl adducts at the adenosine in motifs, such as DRACH, RAC, or RRACH. As such, it influences mRNA splicing,
- Published in Emerging Targets, HTS Assays
No Comments
[Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay
Thursday, 04 May 2023
Interested in DNA damage repair pathways for drug discovery? Join us for a live webinar, where Ha Pham, senior scientist at BellBrook Labs, will be sharing her expertise on using the Transcreener ADPR Assay, a biochemical HTS assay, to study enzymes involved in DNA damage repair. She will use CD38 and PARG as target examples
- Published in Emerging Targets, HTS Assays, Innate Immunity
The Challenging Search for BTK Inhibitors
Tuesday, 27 December 2022
Bruton’s Tyrosine Kinase (BTK) is a 76kDa non-receptor Tec kinase that plays numerous diverse roles in B-cell development, immunity, autoimmunity, infection, and cancer. From stem to stern, it consists of an N-terminal plekstrin homology (PH) domain, a TEC homology (TH) domain, two SRC homology (SH2 and SH3) domains, and a C-terminal kinase domain. Unlike SRC,
- Published in Emerging Targets, HTS Assays, Innate Immunity
SIRT2 Isoforms in Neurodegenerative Diseases & Cancer
Tuesday, 29 November 2022
Silent information regulator type 2 (Sirtuin 2 or SIRT2) is a highly evolutionarily conserved NAD+ dependent deacetylase. SIRT2 is the only Sirtuin that acts in the cytosol. It expresses in almost all tissues, but most abundantly in the central nervous system. While SIRT2 is classified as a type III histone deacetylase, it is also capable
- Published in Emerging Targets, HTS Assays, Innate Immunity, Neurodegenerative Diseases
Can WRN Helicase Inhibitors Treat MSI-H Cancers?
Tuesday, 04 October 2022
Over 100 years ago, Otto Werner first characterized a recessive autosomal disorder that caused premature, but largely typical, aging in adults, starting by the 3rd decade and resulting in death by the 6th decade via myocardial infarction or cancer. This disease, now known as Werner syndrome, is caused by specific alterations in the 162 KDa
- Published in Emerging Targets, HTS Assays, Innate Immunity